Naringenin could block the secretion of TGF-β1 from breast cancer cells, reducing the percentage of CD4+ CD25+ Foxp3 + T cells and suppressing tumor cell migration as well as lung metastasis [253]. This evidence concerns the gene FOXP3 and breast carcinoma.